nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroxyaluminium—VDAC3—hair follicle—skin cancer	0.0499	0.0883	CbGeAlD
Dihydroxyaluminium—VDAC1—hair follicle—skin cancer	0.0475	0.084	CbGeAlD
Dihydroxyaluminium—VDAC3—nipple—skin cancer	0.0338	0.0598	CbGeAlD
Dihydroxyaluminium—Pulmonary congestion—Imiquimod—skin cancer	0.0324	0.0746	CcSEcCtD
Dihydroxyaluminium—VDAC1—nipple—skin cancer	0.0322	0.0569	CbGeAlD
Dihydroxyaluminium—VDAC2—connective tissue—skin cancer	0.0288	0.051	CbGeAlD
Dihydroxyaluminium—VDAC2—epithelium—skin cancer	0.0274	0.0484	CbGeAlD
Dihydroxyaluminium—Respiratory tract congestion—Imiquimod—skin cancer	0.0268	0.0618	CcSEcCtD
Dihydroxyaluminium—VDAC2—skin of body—skin cancer	0.026	0.046	CbGeAlD
Dihydroxyaluminium—VDAC1—connective tissue—skin cancer	0.0228	0.0404	CbGeAlD
Dihydroxyaluminium—VDAC1—epithelium—skin cancer	0.0217	0.0383	CbGeAlD
Dihydroxyaluminium—VDAC3—skin of body—skin cancer	0.0217	0.0383	CbGeAlD
Dihydroxyaluminium—VDAC2—lymphoid tissue—skin cancer	0.0211	0.0373	CbGeAlD
Dihydroxyaluminium—VDAC1—skin of body—skin cancer	0.0206	0.0365	CbGeAlD
Dihydroxyaluminium—VDAC2—female reproductive system—skin cancer	0.0203	0.0359	CbGeAlD
Dihydroxyaluminium—VDAC3—mammalian vulva—skin cancer	0.0198	0.035	CbGeAlD
Dihydroxyaluminium—TNNC1—connective tissue—skin cancer	0.0196	0.0346	CbGeAlD
Dihydroxyaluminium—VDAC1—mammalian vulva—skin cancer	0.0188	0.0332	CbGeAlD
Dihydroxyaluminium—VDAC2—head—skin cancer	0.017	0.03	CbGeAlD
Dihydroxyaluminium—VDAC3—female reproductive system—skin cancer	0.0169	0.0299	CbGeAlD
Dihydroxyaluminium—VDAC1—lymphoid tissue—skin cancer	0.0167	0.0295	CbGeAlD
Dihydroxyaluminium—VDAC1—female reproductive system—skin cancer	0.0161	0.0285	CbGeAlD
Dihydroxyaluminium—VDAC3—head—skin cancer	0.0141	0.025	CbGeAlD
Dihydroxyaluminium—Hyponatraemia—Vismodegib—skin cancer	0.0135	0.0312	CcSEcCtD
Dihydroxyaluminium—VDAC1—head—skin cancer	0.0135	0.0238	CbGeAlD
Dihydroxyaluminium—Dehydration—Vismodegib—skin cancer	0.0125	0.0289	CcSEcCtD
Dihydroxyaluminium—VDAC2—lymph node—skin cancer	0.0119	0.021	CbGeAlD
Dihydroxyaluminium—Cardiovascular disorder—Imiquimod—skin cancer	0.0111	0.0257	CcSEcCtD
Dihydroxyaluminium—VDAC3—lymph node—skin cancer	0.0099	0.0175	CbGeAlD
Dihydroxyaluminium—VDAC1—lymph node—skin cancer	0.00942	0.0167	CbGeAlD
Dihydroxyaluminium—Encephalopathy—Fluorouracil—skin cancer	0.00842	0.0194	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Temozolomide—skin cancer	0.00829	0.0191	CcSEcCtD
Dihydroxyaluminium—TNNC1—lymph node—skin cancer	0.00807	0.0143	CbGeAlD
Dihydroxyaluminium—Extravasation—Bleomycin—skin cancer	0.00797	0.0184	CcSEcCtD
Dihydroxyaluminium—Back pain—Vismodegib—skin cancer	0.00786	0.0181	CcSEcCtD
Dihydroxyaluminium—Extravasation—Dactinomycin—skin cancer	0.00744	0.0171	CcSEcCtD
Dihydroxyaluminium—Urinary retention—Imiquimod—skin cancer	0.00676	0.0156	CcSEcCtD
Dihydroxyaluminium—Extravasation—Fluorouracil—skin cancer	0.0062	0.0143	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Bleomycin—skin cancer	0.00586	0.0135	CcSEcCtD
Dihydroxyaluminium—Pain—Vismodegib—skin cancer	0.00567	0.0131	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Dactinomycin—skin cancer	0.00547	0.0126	CcSEcCtD
Dihydroxyaluminium—Chills—Vemurafenib—skin cancer	0.00517	0.0119	CcSEcCtD
Dihydroxyaluminium—Coma—Fluorouracil—skin cancer	0.00494	0.0114	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Imiquimod—skin cancer	0.00493	0.0113	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Temozolomide—skin cancer	0.00492	0.0113	CcSEcCtD
Dihydroxyaluminium—Back pain—Vemurafenib—skin cancer	0.00486	0.0112	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Imiquimod—skin cancer	0.00474	0.0109	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Vismodegib—skin cancer	0.00454	0.0104	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Fluorouracil—skin cancer	0.00453	0.0104	CcSEcCtD
Dihydroxyaluminium—Thirst—Temozolomide—skin cancer	0.00448	0.0103	CcSEcCtD
Dihydroxyaluminium—Extravasation—Docetaxel—skin cancer	0.00447	0.0103	CcSEcCtD
Dihydroxyaluminium—Chills—Imiquimod—skin cancer	0.00441	0.0102	CcSEcCtD
Dihydroxyaluminium—Vomiting—Vismodegib—skin cancer	0.00422	0.0097	CcSEcCtD
Dihydroxyaluminium—Back pain—Imiquimod—skin cancer	0.00414	0.00953	CcSEcCtD
Dihydroxyaluminium—Infection—Vemurafenib—skin cancer	0.00407	0.00937	CcSEcCtD
Dihydroxyaluminium—Dehydration—Temozolomide—skin cancer	0.00396	0.00912	CcSEcCtD
Dihydroxyaluminium—Nausea—Vismodegib—skin cancer	0.00394	0.00907	CcSEcCtD
Dihydroxyaluminium—Hypotension—Vemurafenib—skin cancer	0.00383	0.00881	CcSEcCtD
Dihydroxyaluminium—Convulsion—Imiquimod—skin cancer	0.00371	0.00854	CcSEcCtD
Dihydroxyaluminium—Oedema—Imiquimod—skin cancer	0.00349	0.00804	CcSEcCtD
Dihydroxyaluminium—Lightheadedness—Docetaxel—skin cancer	0.00349	0.00804	CcSEcCtD
Dihydroxyaluminium—Infection—Imiquimod—skin cancer	0.00347	0.00799	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Imiquimod—skin cancer	0.00341	0.00785	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Fluorouracil—skin cancer	0.0033	0.00761	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Docetaxel—skin cancer	0.00329	0.00757	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Docetaxel—skin cancer	0.00327	0.00753	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Vemurafenib—skin cancer	0.00324	0.00745	CcSEcCtD
Dihydroxyaluminium—Chills—Bleomycin—skin cancer	0.00314	0.00722	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Vemurafenib—skin cancer	0.00302	0.00695	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Docetaxel—skin cancer	0.00299	0.00688	CcSEcCtD
Dihydroxyaluminium—Pain—Imiquimod—skin cancer	0.00299	0.00688	CcSEcCtD
Dihydroxyaluminium—Chills—Dactinomycin—skin cancer	0.00292	0.00673	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Docetaxel—skin cancer	0.00284	0.00655	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Temozolomide—skin cancer	0.00284	0.00654	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Vemurafenib—skin cancer	0.0028	0.00645	CcSEcCtD
Dihydroxyaluminium—Urticaria—Imiquimod—skin cancer	0.00278	0.00639	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Imiquimod—skin cancer	0.00276	0.00636	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Fluorouracil—skin cancer	0.00272	0.00627	CcSEcCtD
Dihydroxyaluminium—Dizziness—Vemurafenib—skin cancer	0.00271	0.00624	CcSEcCtD
Dihydroxyaluminium—Chills—Temozolomide—skin cancer	0.00264	0.00609	CcSEcCtD
Dihydroxyaluminium—Dehydration—Docetaxel—skin cancer	0.00263	0.00606	CcSEcCtD
Dihydroxyaluminium—Vomiting—Vemurafenib—skin cancer	0.00261	0.006	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Imiquimod—skin cancer	0.00257	0.00593	CcSEcCtD
Dihydroxyaluminium—Oedema—Bleomycin—skin cancer	0.00248	0.00571	CcSEcCtD
Dihydroxyaluminium—Back pain—Temozolomide—skin cancer	0.00248	0.00571	CcSEcCtD
Dihydroxyaluminium—Infection—Bleomycin—skin cancer	0.00247	0.00568	CcSEcCtD
Dihydroxyaluminium—Nausea—Vemurafenib—skin cancer	0.00243	0.0056	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Temozolomide—skin cancer	0.00242	0.00557	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Imiquimod—skin cancer	0.00239	0.0055	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Docetaxel—skin cancer	0.00239	0.00549	CcSEcCtD
Dihydroxyaluminium—Hypotension—Bleomycin—skin cancer	0.00232	0.00534	CcSEcCtD
Dihydroxyaluminium—Oedema—Dactinomycin—skin cancer	0.00232	0.00533	CcSEcCtD
Dihydroxyaluminium—Dizziness—Imiquimod—skin cancer	0.00231	0.00532	CcSEcCtD
Dihydroxyaluminium—Vertigo—Temozolomide—skin cancer	0.00231	0.00531	CcSEcCtD
Dihydroxyaluminium—Infection—Dactinomycin—skin cancer	0.0023	0.00529	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Fluorouracil—skin cancer	0.00223	0.00513	CcSEcCtD
Dihydroxyaluminium—Convulsion—Temozolomide—skin cancer	0.00222	0.00512	CcSEcCtD
Dihydroxyaluminium—Vomiting—Imiquimod—skin cancer	0.00222	0.00511	CcSEcCtD
Dihydroxyaluminium—Pain—Bleomycin—skin cancer	0.00212	0.00489	CcSEcCtD
Dihydroxyaluminium—Oedema—Temozolomide—skin cancer	0.00209	0.00482	CcSEcCtD
Dihydroxyaluminium—Infection—Temozolomide—skin cancer	0.00208	0.00479	CcSEcCtD
Dihydroxyaluminium—Nausea—Imiquimod—skin cancer	0.00208	0.00478	CcSEcCtD
Dihydroxyaluminium—Convulsion—Fluorouracil—skin cancer	0.00205	0.00471	CcSEcCtD
Dihydroxyaluminium—Pain—Dactinomycin—skin cancer	0.00198	0.00456	CcSEcCtD
Dihydroxyaluminium—Urticaria—Bleomycin—skin cancer	0.00197	0.00454	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Docetaxel—skin cancer	0.00196	0.00452	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Bleomycin—skin cancer	0.00196	0.00452	CcSEcCtD
Dihydroxyaluminium—Oedema—Fluorouracil—skin cancer	0.00193	0.00444	CcSEcCtD
Dihydroxyaluminium—Infection—Fluorouracil—skin cancer	0.00192	0.00441	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Docetaxel—skin cancer	0.00189	0.00435	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Fluorouracil—skin cancer	0.00188	0.00433	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Dactinomycin—skin cancer	0.00183	0.00421	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Bleomycin—skin cancer	0.00183	0.00421	CcSEcCtD
Dihydroxyaluminium—Hypotension—Fluorouracil—skin cancer	0.0018	0.00415	CcSEcCtD
Dihydroxyaluminium—Pain—Temozolomide—skin cancer	0.00179	0.00412	CcSEcCtD
Dihydroxyaluminium—Chills—Docetaxel—skin cancer	0.00176	0.00405	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Dactinomycin—skin cancer	0.00171	0.00393	CcSEcCtD
Dihydroxyaluminium—Urticaria—Temozolomide—skin cancer	0.00166	0.00383	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Temozolomide—skin cancer	0.00166	0.00381	CcSEcCtD
Dihydroxyaluminium—Back pain—Docetaxel—skin cancer	0.00165	0.0038	CcSEcCtD
Dihydroxyaluminium—Pain—Fluorouracil—skin cancer	0.00165	0.0038	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Dactinomycin—skin cancer	0.00158	0.00365	CcSEcCtD
Dihydroxyaluminium—Vomiting—Bleomycin—skin cancer	0.00158	0.00363	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Temozolomide—skin cancer	0.00154	0.00355	CcSEcCtD
Dihydroxyaluminium—Urticaria—Fluorouracil—skin cancer	0.00153	0.00353	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Fluorouracil—skin cancer	0.00153	0.00351	CcSEcCtD
Dihydroxyaluminium—Convulsion—Docetaxel—skin cancer	0.00148	0.0034	CcSEcCtD
Dihydroxyaluminium—Nausea—Bleomycin—skin cancer	0.00147	0.00339	CcSEcCtD
Dihydroxyaluminium—Vomiting—Dactinomycin—skin cancer	0.00147	0.00339	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Temozolomide—skin cancer	0.00143	0.0033	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Fluorouracil—skin cancer	0.00142	0.00327	CcSEcCtD
Dihydroxyaluminium—Oedema—Docetaxel—skin cancer	0.00139	0.0032	CcSEcCtD
Dihydroxyaluminium—Dizziness—Temozolomide—skin cancer	0.00138	0.00319	CcSEcCtD
Dihydroxyaluminium—Infection—Docetaxel—skin cancer	0.00138	0.00318	CcSEcCtD
Dihydroxyaluminium—Nausea—Dactinomycin—skin cancer	0.00138	0.00316	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Docetaxel—skin cancer	0.00136	0.00313	CcSEcCtD
Dihydroxyaluminium—Vomiting—Temozolomide—skin cancer	0.00133	0.00306	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Fluorouracil—skin cancer	0.00132	0.00304	CcSEcCtD
Dihydroxyaluminium—Hypotension—Docetaxel—skin cancer	0.0013	0.00299	CcSEcCtD
Dihydroxyaluminium—Dizziness—Fluorouracil—skin cancer	0.00128	0.00294	CcSEcCtD
Dihydroxyaluminium—Nausea—Temozolomide—skin cancer	0.00124	0.00286	CcSEcCtD
Dihydroxyaluminium—Vomiting—Fluorouracil—skin cancer	0.00123	0.00282	CcSEcCtD
Dihydroxyaluminium—Pain—Docetaxel—skin cancer	0.00119	0.00274	CcSEcCtD
Dihydroxyaluminium—Nausea—Fluorouracil—skin cancer	0.00115	0.00264	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Docetaxel—skin cancer	0.0011	0.00253	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Docetaxel—skin cancer	0.00103	0.00236	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Docetaxel—skin cancer	0.000953	0.00219	CcSEcCtD
Dihydroxyaluminium—Dizziness—Docetaxel—skin cancer	0.000921	0.00212	CcSEcCtD
Dihydroxyaluminium—Vomiting—Docetaxel—skin cancer	0.000885	0.00204	CcSEcCtD
Dihydroxyaluminium—Nausea—Docetaxel—skin cancer	0.000827	0.0019	CcSEcCtD
